by Linda A. Johnson

This picture offered by Novo Nordisk on Friday, June 4, 2021 exhibits a package deal of injection pens for the corporate’s semaglutide treatment, named Wegovy. On Friday, the Meals and Drug Administration stated this new model of a well-liked diabetes medication might be offered as a weight-loss drug within the U.S. Credit score: Novo Nordisk by way of AP

Regulators on Friday stated a brand new model of a well-liked diabetes medication might be offered as a weight-loss drug within the U.S.

The Meals and Drug Administration accredited Wegovy, a higher-dose model of Novo Nordisk’s diabetes